Cargando…
Complementarity Between a Docking and a High-Throughput Screen in Discovering New Cruzain Inhibitors
[Image: see text] Virtual and high-throughput screens (HTS) should have complementary strengths and weaknesses, but studies that prospectively and comprehensively compare them are rare. We undertook a parallel docking and HTS screen of 197861 compounds against cruzain, a thiol protease target for Ch...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
American Chemical Society
2010
|
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2895358/ https://www.ncbi.nlm.nih.gov/pubmed/20540517 http://dx.doi.org/10.1021/jm100488w |
_version_ | 1782183255742611456 |
---|---|
author | Ferreira, Rafaela S. Simeonov, Anton Jadhav, Ajit Eidam, Oliv Mott, Bryan T. Keiser, Michael J. McKerrow, James H. Maloney, David J. Irwin, John J. Shoichet, Brian K. |
author_facet | Ferreira, Rafaela S. Simeonov, Anton Jadhav, Ajit Eidam, Oliv Mott, Bryan T. Keiser, Michael J. McKerrow, James H. Maloney, David J. Irwin, John J. Shoichet, Brian K. |
author_sort | Ferreira, Rafaela S. |
collection | PubMed |
description | [Image: see text] Virtual and high-throughput screens (HTS) should have complementary strengths and weaknesses, but studies that prospectively and comprehensively compare them are rare. We undertook a parallel docking and HTS screen of 197861 compounds against cruzain, a thiol protease target for Chagas disease, looking for reversible, competitive inhibitors. On workup, 99% of the hits were eliminated as false positives, yielding 146 well-behaved, competitive ligands. These fell into five chemotypes: two were prioritized by scoring among the top 0.1% of the docking-ranked library, two were prioritized by behavior in the HTS and by clustering, and one chemotype was prioritized by both approaches. Determination of an inhibitor/cruzain crystal structure and comparison of the high-scoring docking hits to experiment illuminated the origins of docking false-negatives and false-positives. Prioritizing molecules that are both predicted by docking and are HTS-active yields well-behaved molecules, relatively unobscured by the false-positives to which both techniques are individually prone. |
format | Text |
id | pubmed-2895358 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2010 |
publisher | American Chemical Society |
record_format | MEDLINE/PubMed |
spelling | pubmed-28953582010-07-01 Complementarity Between a Docking and a High-Throughput Screen in Discovering New Cruzain Inhibitors Ferreira, Rafaela S. Simeonov, Anton Jadhav, Ajit Eidam, Oliv Mott, Bryan T. Keiser, Michael J. McKerrow, James H. Maloney, David J. Irwin, John J. Shoichet, Brian K. J Med Chem [Image: see text] Virtual and high-throughput screens (HTS) should have complementary strengths and weaknesses, but studies that prospectively and comprehensively compare them are rare. We undertook a parallel docking and HTS screen of 197861 compounds against cruzain, a thiol protease target for Chagas disease, looking for reversible, competitive inhibitors. On workup, 99% of the hits were eliminated as false positives, yielding 146 well-behaved, competitive ligands. These fell into five chemotypes: two were prioritized by scoring among the top 0.1% of the docking-ranked library, two were prioritized by behavior in the HTS and by clustering, and one chemotype was prioritized by both approaches. Determination of an inhibitor/cruzain crystal structure and comparison of the high-scoring docking hits to experiment illuminated the origins of docking false-negatives and false-positives. Prioritizing molecules that are both predicted by docking and are HTS-active yields well-behaved molecules, relatively unobscured by the false-positives to which both techniques are individually prone. American Chemical Society 2010-06-11 2010-07-08 /pmc/articles/PMC2895358/ /pubmed/20540517 http://dx.doi.org/10.1021/jm100488w Text en Copyright © 2010 American Chemical Society http://pubs.acs.org This is an open-access article distributed under the ACS AuthorChoice Terms & Conditions. Any use of this article, must conform to the terms of that license which are available at http://pubs.acs.org. |
spellingShingle | Ferreira, Rafaela S. Simeonov, Anton Jadhav, Ajit Eidam, Oliv Mott, Bryan T. Keiser, Michael J. McKerrow, James H. Maloney, David J. Irwin, John J. Shoichet, Brian K. Complementarity Between a Docking and a High-Throughput Screen in Discovering New Cruzain Inhibitors |
title | Complementarity Between a Docking and a High-Throughput Screen in Discovering New Cruzain Inhibitors |
title_full | Complementarity Between a Docking and a High-Throughput Screen in Discovering New Cruzain Inhibitors |
title_fullStr | Complementarity Between a Docking and a High-Throughput Screen in Discovering New Cruzain Inhibitors |
title_full_unstemmed | Complementarity Between a Docking and a High-Throughput Screen in Discovering New Cruzain Inhibitors |
title_short | Complementarity Between a Docking and a High-Throughput Screen in Discovering New Cruzain Inhibitors |
title_sort | complementarity between a docking and a high-throughput screen in discovering new cruzain inhibitors |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2895358/ https://www.ncbi.nlm.nih.gov/pubmed/20540517 http://dx.doi.org/10.1021/jm100488w |
work_keys_str_mv | AT ferreirarafaelas complementaritybetweenadockingandahighthroughputscreenindiscoveringnewcruzaininhibitors AT simeonovanton complementaritybetweenadockingandahighthroughputscreenindiscoveringnewcruzaininhibitors AT jadhavajit complementaritybetweenadockingandahighthroughputscreenindiscoveringnewcruzaininhibitors AT eidamoliv complementaritybetweenadockingandahighthroughputscreenindiscoveringnewcruzaininhibitors AT mottbryant complementaritybetweenadockingandahighthroughputscreenindiscoveringnewcruzaininhibitors AT keisermichaelj complementaritybetweenadockingandahighthroughputscreenindiscoveringnewcruzaininhibitors AT mckerrowjamesh complementaritybetweenadockingandahighthroughputscreenindiscoveringnewcruzaininhibitors AT maloneydavidj complementaritybetweenadockingandahighthroughputscreenindiscoveringnewcruzaininhibitors AT irwinjohnj complementaritybetweenadockingandahighthroughputscreenindiscoveringnewcruzaininhibitors AT shoichetbriank complementaritybetweenadockingandahighthroughputscreenindiscoveringnewcruzaininhibitors |